Quantcast
Last updated on April 18, 2014 at 0:14 EDT

Latest Incyte Corporation Stories

2012-06-08 06:25:57

BERLIN, June 8, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis (RA). The results were presented as a late-breaking oral presentation at the European League Against Rheumatism's (EULAR) Annual European Congress of Rheumatology [EULAR...

2011-01-27 05:30:00

INDIANAPOLIS, Jan. 27, 2011 /PRNewswire/ -- Higher volume drove four percent revenue growth in Q4. Gross margin improvements in Q4 led to growth in operating income. Fourth quarter earnings per share grew to $1.05 (reported), or $1.11 (non-GAAP). Full-year 2010 revenue topped $23 billion as eight human pharmaceutical medicines and the company's animal health business all exceed $1 billion in annual sales. Full-year 2010 earnings per share grew to $4.58 (reported), or $4.74 (non-GAAP)....

2010-01-28 05:30:00

INDIANAPOLIS, Jan. 28 /PRNewswire-FirstCall/ -- Double-digit revenue growth in Q4 driven by higher volume Weaker dollar results in decreased Q4 gross margin Company delivers Q4 earnings per share of $.83 (reported) or $.91 (pro forma non-GAAP) Full-year 2009 EPS rises to $3.94 (reported) or $4.42 (pro forma non-GAAP) Eight products each exceed $1 billion in annual sales 2010 EPS guidance range reconfirmed at $4.65 to $4.85 Eli Lilly and Company (NYSE: LLY) today announced financial...

2009-12-21 06:30:00

INDIANAPOLIS and WILMINGTON, Del., Dec. 21 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) announced today that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Incyte's oral JAK1/JAK2 inhibitor, INCB28050, and certain follow on compounds, for inflammatory and autoimmune diseases. The lead compound, INCB28050, is currently being studied in a six-month...

2009-05-19 08:00:00

RESEARCH TRIANGLE PARK, N.C., May 19 /PRNewswire/ -- ArtusLabs, Inc. (www.artuslabs.com), the leader in scientifically-aware data management systems, today announced a collaborative license agreement with Incyte Corporation to address two prevalent industry problems. The first is to more effectively access and visualize scientific data and display the results in a web based interface. The second is a methodology and process for automatically harvesting and correlating analytical data from...

2008-10-26 19:01:19

Incyte Corporation (Nasdaq:INCY) announced today the presentation of clinical results from a 28-day Phase IIa trial of INCB18424, its orally available janus kinase (JAK) inhibitor, in patients with rheumatoid arthritis (RA). Results from the 50-patient placebo-controlled trial demonstrated that three of the four doses of INCB18424 evaluated (15 mg BID, 25 mg BID and 50 mg QD) produced impressive clinical benefits and all of the doses were well tolerated. American College of Rheumatology...

2008-09-18 09:00:11

Incyte Corporation (Nasdaq:INCY) reported positive results from two 28-day Phase IIa clinical trials of topical INCB18424, a selective janus-associated kinase (JAK) inhibitor, in patients with mild to moderate psoriasis. Results from the first study (Study 201), a Phase IIa dose-escalation trial involving 28 patients, demonstrated that INCB18424 was well tolerated at all doses and significantly improved overall total lesion score and each component of the total lesion score (thickness,...

2008-07-29 18:00:51

Incyte Corporation (Nasdaq:INCY) today announced its second quarter 2008 financial results and reported continued progress in several lead clinical programs. Paul Friedman, M.D., President and CEO of Incyte, stated, "During the second quarter, we presented clinical findings at several scientific conferences from our ongoing phase II trials demonstrating that our lead JAK inhibitor compound, INCB18424, was well tolerated and provided rapid and profound effects in patients with...